GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » Earnings Yield (Joel Greenblatt) %

Clover Biopharmaceuticals (HKSE:02197) Earnings Yield (Joel Greenblatt) % : -39.53% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals Earnings Yield (Joel Greenblatt) %?

Clover Biopharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was HK$331.40 Mil. Clover Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-131.05 Mil. Clover Biopharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -39.53%.

The historical rank and industry rank for Clover Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

HKSE:02197' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -56850.6   Med: -161.68   Max: 711.39
Current: -714.29

During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of Clover Biopharmaceuticals was 711.39%. The lowest was -56850.60%. And the median was -161.68%.

HKSE:02197's Earnings Yield (Joel Greenblatt) % is ranked worse than
99.5% of 1404 companies
in the Biotechnology industry
Industry Median: -15.445 vs HKSE:02197: -714.29

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Clover Biopharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Clover Biopharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Clover Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals Earnings Yield (Joel Greenblatt) % Chart

Clover Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
- - -60.61 -142.86 -39.53

Clover Biopharmaceuticals Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial -60.61 - -142.86 - -39.53

Competitive Comparison of Clover Biopharmaceuticals's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Clover Biopharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clover Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Clover Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.



Clover Biopharmaceuticals Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Clover Biopharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-131.052/331.3988
=-39.55 %

For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.



Clover Biopharmaceuticals  (HKSE:02197) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Clover Biopharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clover Biopharmaceuticals (HKSE:02197) Business Description

Traded in Other Exchanges
N/A
Address
1598-1601 West Nanjing Road, 49th Floor, Park Place, Jing’an District, Shanghai, CHN
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.
Executives
Liang Peng 2101 Beneficial owner
Liang Joshua G 2501 Other
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Aut-xxi Investment Holdings Limited 2201 Interest of corporation controlled by you
Jnry V Holdings Limited 2101 Beneficial owner
Aut-xxi Hk Holdings Limited 2101 Beneficial owner
Aut-xxi Holdings Limited 2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Super Novel International Limited 2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals (HKSE:02197) Headlines

No Headlines